Mr. John W. Ripple served as Chief Executive Officer of Permeon Biologics, Inc. Mr. Ripple joined Permeon Biologics in 2013. He serves as an advisor to the MIT Deshpande Center for Technological Innovation and the MIT Venture Mentoring Service. He served as Chief Executive Officer of Ensemble Therapeutics Corporation until October 2, 2017. Mr. Ripple served as the Chief Executive Officer at Virdante Pharmaceuticals, Inc. Mr. Ripple served as an Acting President of Biogen Idec Hemophilia Inc. (a/k/a Syntonix Pharmaceuticals, Inc.) since July 2005 and its Chief Executive Officer since December 2005. He joined Syntonix in Spring, 2002 as Vice President of Corporate Development. Mr. Ripple was with Wyeth Pharmaceuticals where he served as an Assistant Vice President, Global Business Development and served as Director of Corporate Development for Genetics Institute. In both these positions, he played an instrumental role in establishing partnering strategies and negotiating transactions with biotechnology and pharmaceutical companies in the United States, Europe and Japan. His other business experience includes medical device marketing and management consulting. Mr. Ripple started his career as an aerospace engineer working for NASA. Mr. Ripple also serves on the Board of Directors of Therapyx Inc. and on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA). He served as a Director of Syntonix Pharmaceuticals, Inc. and Virdante Pharmaceuticals, Inc. Mr. Ripple is also a registered patent agent. He received a B.S. in Mechanical Engineering from Bucknell University and an M.B.A. from Harvard Business School. Mr. John W. Ripple served as Chief Executive Officer of Permeon Biologics, Inc. Mr. Ripple joined Permeon Biologics in 2013. He serves as an advisor to the MIT Deshpande Center for Technological Innovation and the MIT Venture Mentoring Service. He served as Chief Executive Officer of Ensemble Therapeutics Corporation until October 2, 2017. Mr. Ripple served as the Chief Executive Officer at Virdante Pharmaceuticals, Inc. Mr. Ripple served as an Acting President of Biogen Idec Hemophilia Inc. (a/k/a Syntonix Pharmaceuticals, Inc.) since July 2005 and its Chief Executive Officer since December 2005. He joined Syntonix in Spring, 2002 as Vice President of Corporate Development. Mr. Ripple was with Wyeth Pharmaceuticals where he served as an Assistant Vice President, Global Business Development and served as Director of Corporate Development for Genetics Institute. In both these positions, he played an instrumental role in establishing partnering strategies and negotiating transactions with biotechnology and pharmaceutical companies in the United States, Europe and Japan. His other business experience includes medical device marketing and management consulting. Mr. Ripple started his career as an aerospace engineer working for NASA. Mr. Ripple also serves on the Board of Directors of Therapyx Inc. and on the Board of Overseers at the Marine Biological Laboratory (Woods Hole, MA). He served as a Director of Syntonix Pharmaceuticals, Inc. and Virdante Pharmaceuticals, Inc. Mr. Ripple is also a registered patent agent. He received a B.S. in Mechanical Engineering from Bucknell University and an M.B.A. from Harvard Business School.

Blood Research & Hematologic Diseases